JCK-AP session 7-2 (III-JCKAP7-2)
Interventional cardiology 2

[III-JCKAP7-2-3] Results of Balloon Pulmonary Valvuloplasty Treatment for Valvar Pulmonary stenosis

^○Khongor Ganbold¹, Bat-Undrakh Jargal², Anu-Ujin Sodnompil³, Batsuuri Bathuyag⁴, Undral Badrakh⁵, Bolormaa Towuudorj⁶ (1.National Center for Maternal and Child Health, Ulaanbaatar, 2.National Center for Maternal and Child Health, Ulaanbaatar, Department of Pediatric Cardiology, 3.National Center for Maternal and Child Health, Ulaanbaatar, Department of Pediatric Cardiology, 4.National Center for Maternal and Child Health, Ulaanbaatar, Department of Pediatric Cardiology, 5.National Center for Maternal and Child Health, Ulaanbaatar, Department of Pediatric Cardiology, 6.National Center for Maternal and Child Health , Ulaanbaatar, Department of Pediatric Cardiology)

キーワード： Congenital heart disease, , Valvar Pulmonary stenosis(vPS), Transcatheter balloon valvuloplasty Introduction

Objectives The purpose of this study was to report our initial experience of transcatheter balloon valvuloplasty in patients with vPS in our center. Materials and methods This study was a retrospective review of patients younger than 16 years old, who underwent balloon pulmonary valvuloplasty at our Catheter Laboratory of the National center for maternal and child health with a diagnosis of vPS between 2019 and 2023. We analyzed patients' profile, Doppler echo estimated systolic peak right ventricle to pulmonary artery pressure gradient, and systolic right ventricular pressure before and after balloon dilation. Results: The study enrolled 49 consecutive pediatric patients with vPS. The age and body weight ranged from 1-192 (median 12) months and 3.1-61.0(8.2) kg, respectively. The pulmonary valve annular diameter ranged from 5-23 (10) mm, while balloon diameter ranged from 0.7-1.4 (1.1) times to valve annular diameter. Systolic right ventricular pressure, and echo estimated pressure gradient changed from 41-163 (mean ±SD, 88±26) mmHg to 21-110(47±20) mmHg, and from from 45-135 (85±18) mmHg to 20-115(47±19) mmHg, respectively (p<0.08). In 15 patients, pressure gradient remained over 50 mmHg. No patients developed pulmonary regurgitation worse than moderate, while we did not experience no other adverse events.Conclusion The transcatheter treatment of vPS at the Cardiac Catheter Laboratory of the National Center for Maternal and Child Health has increased from year to year, and it is an effective technique in the treatment of vPS. Further experience will be necessary.